Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?

Giovanni Grandi, Carlo Bastianelli, Manuela Farris

Open source

DOI
10.1080/13625187.2026.2718925
Published
2026-08-20
Container
The European Journal of Contraception & Reproductive Health Care
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/13625187.2026.2718925,
  title = {Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?},
  author = {Giovanni Grandi and Carlo Bastianelli and Manuela Farris},
  year = {2026},
  journal = {The European Journal of Contraception \& Reproductive Health Care},
  doi = {10.1080/13625187.2026.2718925},
  url = {https://doi.org/10.1080/13625187.2026.2718925}
}

RIS

TY  - JOUR
TI  - Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?
AU  - Giovanni Grandi
AU  - Carlo Bastianelli
AU  - Manuela Farris
PY  - 2026
JO  - The European Journal of Contraception & Reproductive Health Care
DO  - 10.1080/13625187.2026.2718925
UR  - https://doi.org/10.1080/13625187.2026.2718925
ER  - 

APA

Grandi, G., Bastianelli, C., & Farris, M. (2026). Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?. The European Journal of Contraception & Reproductive Health Care. https://doi.org/10.1080/13625187.2026.2718925

Source records